• 1.
    Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707714.
  • 2.
    Castelli WP, Garrison RJ, Wilson PWF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:28352838.
  • 3.
    Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:815.
  • 4.
    Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373381.
  • 5.
    Miller NE, Thelle DS, Forde OH, et al. The Tromsø heart-study: High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965968.
  • 6.
    Perova NV, Organov RG, Williams DH, et al. Association of high-density-lipoprotein cholesterol with mortality and other risk factors for major chronic noncommunicable disease in samples of US and Russian men. Ann Epidemiol. 1995;3:179185.
  • 7.
    Stensvold I, Urdal P, Thurmer H, et al. High-density lipoprotein cholesterol and coronary, cardiovascular, and all cause mortality among middle-aged Norwegian men and women. Eur Heart J. 1992;13:11551163.
  • 8.
    Enger SC, Hjermann I, Foss OP, et al. High density lipoprotein cholesterol and myocardial infarction or sudden coronary death: a prospective case-control study in middle-aged men of the Oslo study. Artery. 1979;5:170181.
  • 9.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:12451255.
  • 10.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med. 1987;317:12371245.
  • 11.
    Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410418.
  • 12.
    Rahilly-Tierney C, Bowman TS, Djousse L, et al. Change in high-density lipoprotein cholesterol and coronary heart disease in apparently healthy male physicians. Am J Cardiol. 2008;102:16631667.
  • 13.
    Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target. JAMA. 2007;298:786798.
  • 14.
    Leon AS, Gaskill SE, Rice T, et al. Variability in the response of HDL cholesterol to exercise training in the HERITAGE Family Study. Int J Sports Med. 2002;23:19.
  • 15.
    Asztalos B, Lefevre M, Wong L, et al. Differential response to low-fat diet between low and normal HDL-C cholesterol subjects. J Lipid Res. 2000;41:321328.
  • 16.
    Gaziano JM, Buring JE, Breslow JL, et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med. 1993;329:18291834.
  • 17.
    Ellison RC, Zhang Y, Qureshi MM, et al; Investigators of the NHLBI Family Heart Study. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2004;147: 529535.
  • 18.
    Weisskopf MG, Jain N, Nie H, et al. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. Circulation. 2009;120: 10561064.
  • 19.
    Criqui MH. Triglycerides and coronary heart disease revisited (again). Ann Intern Med. 2007;147:425427.
  • 20.
    American Heart Association Web site. NHLBI decision to stop AIM-HIGH trial. Accessed June 8, 2011.